Metabolic syndrome and adverse clinical outcomes in patients with bipolar disorder by Ya-Mei Bai et al.
RESEARCH ARTICLE Open Access
Metabolic syndrome and adverse clinical
outcomes in patients with bipolar disorder
Ya-Mei Bai1,2*, Cheng-Ta Li1,2, Shih-Jen Tsai1,2, Pei-Chi Tu1,2, Mu-Hong Chen1,2 and Tung-Ping Su1,2
Abstract
Background: Metabolic syndrome (MetS) is highly prevalent among patients with bipolar disorder. MetS may cause
complications in the brain, but studies investigating MetS-associated clinical psychiatric outcomes remain scant.
Methods: We enrolled clinically stable outpatients with bipolar disorder aged 18–65 years and performed anthropometric
and fasting biochemical assessments to investigate MetS prevalence. We then performed clinical assessments by using the
Young Mania Rating Scale for manic symptoms, the Montgomery–Åsberg Depression Rating Scale for
depressive symptoms, the Positive and Negative Symptom Scale for psychotic symptoms, the Involuntary Movement
Scale for tardive dyskinesia, the Barnes Akathisia Rating Scale for akathisia, the Udvalg for Kliniske Undersogelser for
general side effects, the Schedule for Assessment of Insight for insight, the Global Assessment of Functioning scale for
global functioning, and the Wisconsin Card Sorting Test (WCST) for cognitive executive function.
Results: In total, 143 patients were enrolled and had a MetS prevalence of 29.4%. The patients treated with atypical
antipsychotics plus mood stabilizers (36.3%) and atypical antipsychotics alone (36.0%) had a significantly higher
prevalence of MetS than did those treated with mood stabilizers alone (10.5%; p = 0.012). According to multivariate
regression analyses adjusted for age, sex, smoking status, bipolar disorder subtype (I or II), pharmacological treatment
duration, and psychiatric medication, compared with patients without MetS, those with MetS had significantly more
previous hospitalizations (p = 0.036), severer tardive dyskinesia (p = 0.030), poorer insight (p = 0.036), poorer global
function (p = 0.046), and more impaired executive function (conceptual level response on the WCST; p = 0.042).
Conclusions: Our results indicated that patients with comorbid bipolar disorder and MetS have more adverse clinical
outcomes than those without, with more hospitalizations, severer tardive dyskinesia, poorer insight, poorer global
function, and more impaired executive function. Monitoring MetS is crucial for assessing not only physical burden, but
also psychiatric outcomes.
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Background
Metabolic syndrome (MetS) is highly prevalent
(16.7%–67%) among patients with bipolar disorder in
many countries [1–3]. Bipolar disorder and MetS have
common risk factors, including endocrine distur-
bances, sympathetic nervous system dysregulation,
and behavior patterns such as physical inactivity and
overeating [4, 5]. In addition, commonly used pharmaco-
logical bipolar disorder treatments, such as mood stabilizers
and antipsychotics, may intensify the medical burden by
causing weight gain and metabolic disturbances, such as
alterations in lipid and glucose metabolism [6, 7]. Comorbid
MetS and bipolar disorder are associated with a high risk of
cardiovascular disease [3, 5, 8], a two-fold increase in mor-
tality [9], and a 10–20-year shortening of life expectancy
[10]. Studies have shown that obesity and metabolic diseases
are associated with poor clinical outcome in bipolar
disorder. Fagiolini et al. reported that 35.4% of 175 patients
with bipolar disorder were obese and that these patients had
more previous depressive and manic episodes as well as
exhibited a significantly shorter time to recurrence during
the maintenance phase than nonobese patients did [11].
Similarly, Calkin et al. reported that 39.1% of 276 patients
with bipolar disorder were obese and that these patients had
a longer illness duration, poorer global function, more
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disability, and poorer response to lithium than nonobese pa-
tients did [12]. In addition, obesity in bipolar disorder is
associated with illness severity, particularly in relation to
depression [13–15], unfavorable course of illness [15], and
poor cognitive function [16–19]. Compared with euglycemic
patients, those with bipolar disorder and type 2 diabetes or
insulin resistance have significantly higher risk of a chronic
course, rapid cycling, and bipolar disorder refractory to lith-
ium treatment [20–22].
Nevertheless, studies investigating MetS-associated
clinical psychiatric outcomes remain scant. MetS is a
multidimensional entity that includes visceral obesity,
dyslipidemia, hyperglycemia, and hypertension. MetS
may cause complications in the brain: In an animal
study, chronic hyperglycemia and insulin resistance were
reported as risk factors for neuronal death through in-
duction of a state of oxidative stress and inflammatory
response, thus affecting cognitive processes [23]. Patients
with MetS showed a significant reduction in mean
cortical thickness and volume in both hemispheres com-
pared with controls, suggesting an initial neurodegenera-
tive process and cognitive deterioration with MetS, even
at a preclinical stage [24]. Furthermore, four studies of
topiramate as an add-on therapy in patients with bipolar
disorder showed that weight reduction is associated with
a significant reduction in both depressive and manic
symptoms [25–28]. These interventions are potentially
efficacious in ameliorating disturbed biological pathways,
particularly those mediating inflammation and oxidative
stress, and reducing the rate of neuroprogressive distur-
bances in bipolar disorders [29]. In this study, we inves-
tigated the association between MetS and clinical
outcomes of patients with bipolar disorder. We hypothe-
sized that patients with comorbid bipolar disorder and
MetS have more adverse clinical outcomes than those
without MetS do.
Methods
This study was conducted in a psychiatric outpatient
clinic of a university medical center hospital. The patient
inclusion criteria were as follows: outpatients with bipo-
lar disorder (DSM-IV), and those aged 18–65 years with
a Clinical Global Impression-Severity rating for bipolar
disorder of ≤3. The exclusion criteria were any DSM-IV
diagnosis of a lifetime history of schizophrenia, mental
retardation, or organic mental disorder, and those cur-
rently pregnant or breastfeeding. All patients provided
written informed consent before inclusion. The study
was approved by the Institutional Review Board of Taipei
Veterans General Hospital and conducted in accordance
with the Declaration of Helsinki.
The medical and psychiatric histories of the patients
were reviewed. Anthropometric and fasting biochemical
assessments were performed to investigate MetS prevalence
according to the 2005 International Diabetes Federation
Asia criteria; a waist circumference of >90 cm in men or
>80 cm in women was the essential criterion of central
obesity in addition to any two of the following criteria: (a)
fasting serum triglyceride levels of ≥150 mg/dL, (b) fasting
high-density lipoprotein cholesterol levels of <40 mg/dL in
men or <50 mg/dL in women, (c) blood pressure of ≥130/
85 mmHg, or (d) a fasting glucose level of ≥100 mg/dL.
Patients receiving medication for hypertension, diabetes, or
hyperlipidemia were considered to fulfill the MetS compo-
nents criteria. We used the following scales for clinical as-
sessment: the Young Mania Rating Scale (YMRS) for manic
symptoms, the Montgomery–Åsberg Depression Rating
Scale (MADRS) for depressive symptoms, the Positive and
Negative Symptom Scale (PANSS) for psychotic symptoms,
the Simpson–Angus Scale (SAS) for extrapyramidal side
effects [30], the Abnormal Involuntary Movement Scale
(AIMS) for tardive dyskinesia [31], the Barnes Akathisia
Rating Scale (BARS) for akathisia [32], the Udvalg for
Kliniske Undersogelser for general side effects [33], the
Schedule for Assessment of Insight (SAI) for insight [34],
and the Global Assessment of Functioning (GAF) scale for
functioning. Furthermore, cognitive executive function
was assessed using the Wisconsin Card Sorting Test
(WCST). All clinical assessments were conducted by
Dr. Bai (first author).
Patient characteristics were evaluated through descrip-
tive analyses. Patients with and without MetS were com-
pared using a chi-square test for categorical data and the
Student t test for continuous data. The Fisher exact test
was used if fewer than five data points were expected to
be greater than 20% of the cells in the contingency table.
All tests were based on their two-tailed alternatives. The
clinical outcomes of the patients with and without MetS
were further compared using multivariate regression
analyses adjusted for age, sex, smoking status, bipolar
disorder subtype (I or II), pharmacological treatment
duration, and psychiatric medication (monotherapy or
combination therapy). The level of significance was set
at a p value of 0.05. All statistical analyses were per-
formed using SPSS 11.5 (SPSS Inc., Chicago, IL, USA).
Results
In total, we enrolled 143 outpatients with bipolar
disorder (66.4% women) with an average age of 44.8 ±
12.0 years. The prevalence of MetS was 29.4%. Age, sex,
education, pharmacological treatment duration for bipo-
lar disorder, suicide history, bipolar subtype (I or II), as
well as severity of manic (YMRS), depressive (MADRS),
and psychotic (PANSS) symptoms did not differ signifi-
cantly between the patients with and without MetS. The
patients treated with atypical antipsychotics plus mood
stabilizers (36.3%) and atypical antipsychotics alone
(36.0%) had a significantly higher MetS prevalence than
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did those treated with mood stabilizers alone (10.5%; p =
0.012). Univariate analysis showed that compared with the
patients without MetS, those with MetS had significantly
more previous hospitalizations (p = 0.024), more first mood
episodes with mania (p= 0.033), more extrapyramidal side
effects (SAS; p= 0.003), higher incidence of akathisia (BARS;
p= 0.034), higher incidence of involuntary movement dis-
order (AIMS; p= 0.043), poorer global functioning (GAF; p
= 0.035), poorer insight (SAI; p= 0.027), and more impaired
executive function (conceptual level response on the WCST;
p= 0.007). The patients with MetS also had significantly
more medical comorbidities than those without MetS did
(71.4% vs. 32.3%, p < 0.0001), including hypertension (54.8%
vs. 13.9%, p < 0.0001), hyperlipidemia (26.2% vs. 5.9%,
p = 0.001), and diabetes mellitus (23.8% vs. 4%, p = 0.001).
Because smoking status [35, 36], bipolar disorder subtype
[37], illness duration [38, 39], and psychiatric medications
[40, 41] may influence clinical outcomes, we used multi-
variate regression analyses adjusted for age, sex, smoking
status, bipolar disorder subtype (I or II), pharmacological
treatment duration, and psychiatric medication (mood sta-
bilizers alone, atypical antipsychotics alone, or atypical anti-
psychotics plus mood stabilizers). We observed that
compared with the patients without MetS, those with MetS
had significantly more previous hospitalizations (p = 0.036),
severer tardive dyskinesia (AIMS; p = 0.030), poorer insight
(SAI; p = 0.036), poorer global function (GAF; p = 0.046),
and more impaired executive function (conceptual level
response on the WCST; p = 0.042; Fig. 1; Tables 1 and 2).
Discussion
Our study showed that the prevalence of MetS was
29.4% among patients with bipolar disorder, comparable
to the previously reported 33.9% in Taiwan [42] and
16.7%–67% in other countries [1]. The frequent cooccur-
rence of bipolar disorder and MetS may be characterized
by the common genetic links, interconnected pathophys-
iologies, and interacting biological networks with struc-
tural and functional abnormalities in multiple cortical
and subcortical brain regions subservient to cognitive
and affective processing [1, 4, 5, 29]. Furthermore, many
commonly used pharmacological treatments for bipolar
disorder, antipsychotics, and mood stabilizers increase
both weight and MetS risk [1, 3, 43, 44]. In this study,
we demonstrated that patients treated with atypical anti-
psychotics plus mood stabilizers and atypical antipsy-
chotics alone had a significantly higher MetS prevalence
than those treated with mood stabilizers alone did. Our
results were consistent with previous study results, in
which cotreatment with mood stabilizers plus antipsy-
chotics increased MetS risk [44, 45]. A comparative ana-
lysis of 32 double-blind, randomized, placebo-controlled
trials showed that antipsychotics caused more weight
gain than did mood stabilizers in youths [46]. Currently,
many atypical antipsychotics are recommended as first-
line monotherapy or in combination with mood stabi-
lizers to improve the efficacy of bipolar disorder treat-
ment [40, 41, 47–49]. Our results suggest that
efficacious advantages of antipsychotics in bipolar
Fig. 1 Comparison of clinical outcomes between patients with and without metabolic syndrome using multivariate regression analyses with adjustments
of age, gender, smoking, subtype of bipolar disorder, pharmacological treatment duration, and psychiatric medication group
Bai et al. BMC Psychiatry  (2016) 16:448 Page 3 of 9
Table 1 Comparison of characteristics between bipolar patients with and without metabolic syndrome
Patients with metabolic
syndrome (n = 42)
Patients without metabolic
syndrome (n = 101)
df, p-value
Age (year) 47.5 ± 11.2 43.7 ± 12.2 n.s.
Gender (F, %) 67.9% 69.8% n.s.
Education (more than 12 years %) 33.3% 33.7% n.s.
Occupation (regular work %) 28.6% 33.7% n.s.
Age at onset of bipolar disorder 31.5 ± 12.7 28.4 ± 11.7 n.s.
Treatment Duration of bipolar disorder 13.9 ± 11.2 13.1 ± 10.7 n.s.
Smoking (%) 31% 23.8% n.s.
Times of hospitalization 4.1 ± 4.9 2.5 ± 2.9 df = 47.7,P = 0.024
History of suicide attempt (%) 42.9% 47.5% n.s.
Subtype of bipolar disorder (bipolar I %) 69% 59.4% n.s.
Pharmacological treatment groups 52.4% 43.6% n.s.
[mood stabilizers only] 9.5% 33.7% df = 2,P = 0.012
[atypical antipsychotics only] 21.4% 15.8%
[atypical antipsychotics plus mood stabilizers] 69% 50.5%
First mood episode with mania/hypomania (%) 52.5% 32.0% df = 1,P = 0.033
Young Mania Rating Scale (YMRS) 5.3 ± 5.0 4.7 ± 4.9 n.s.
Montgomery Åsberg Depression Rating Scale (MADRS) 8.2 ± 7.4 9.2 ± 9.1 n.s.
Positive and Negative Symptom Scale (PANSS) 41.6 ± 12.6 39.4 ± 11.6 n.s.
Simpson-Angus Scale (SAS) 3.6 ± 4.7 2.1 ± 4.0 df = 67.6,P = 0.046
Abnormal Involuntary Movement Scale (AIMS) 1.8 ± 4.4 0.5 ± 2.4 df = 51.5,P = 0.021
Barnes Akathesia scale (BANS) 0.1 ± 0.6 0.2 ± 0.9 n.s.
Udvalg for Kliniske Undersogelser (UKU) 5.7 ± 3.3 4.7 ± 4.0 n.s.
Schedule for Assessment of Insight (SAI) 16.2 ± 4.9 18.1 ± 4.4 df = 140,P = 0.027
Global Assessment of Functioning scale (GAF) 67.1 ± 11.7 71.5 ± 11.0 df = 141,P = 0.035
Level of lithium (n = 33) 0.51 ± 0.21 0.74 ± 0.62 n.s.
Level of valproic acid (n = 52) 55.0 ± 35.3 40.8 ± 28.5 n.s.
Level of carbamazapine (n = 4) – 6.2 ± 1.7 –
Wisconsin Card Sorting Test (WCST)
Conceptual level response %
34.2 ± 12.5 41.4 ± 11.7 df = 104,P = 0.007
Body Mass Index (BMI) 30.2 ± 4.2 24.8 ± 4.8 df = 141,P < 0.0001
waist circumference > 90 cm in males
or > 80 cm in females
100% 42.6% df = 1,P < 0.0001
fasting serum triglyceride levels≧150 mg/dL 69% 14.9% df = 1,P < 0.0001
fasting high density lipoprotein (HDL)
cholesterol < 40 mg/dL in men or
<50 mg/dL in women
73.8% 13.9% df = 1,P < 0.0001
blood pressure≧130/85 mmHg 78.6% 28.7% df = 1,P < 0.0001
fasting glucose≧100 mg/dL 47.6% 10.9% df = 1,P < 0.0001
Waist circumference (cm) 97.1 ± 9.7 81.3 ± 11.2 df = 100,P < 0.0001
Systolic blood pressure (mmHg) 131.5 ± 17.1 120.6 ± 16.9 df = 141,P = 0.001
Diastolic blood pressure (mm Hg) 82.1 ± 10.5 75.9 ± 11.4 df = 141,P = 0.003
Triglyceride (microg/ dL) 198.4 ± 122.1 101.4 ± 69.4 df = 52.4,P < 0.0001
High density lipoprotein (HDL) (microg/ dL) 41.6 ± 9.3 60.9 ± 15.6 df = 123.6,P < 0.0001
Glucose (microg/ dL) 101.8 ± 37.7 87.7 ± 16.9 df = 46.7,P = 0.026
Insulin (pg/ml) 13.7 ± 10.7 8.0 ± 13.6 df = 133,P = 0.019
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disorder treatment should be balanced with their greater
MetS risk.
To investigate the role of MetS in the clinical out-
comes, we used multivariate regression analyses adjusted
for age, sex, smoking status, bipolar disorder subtype
(I or II), pharmacological treatment duration, and
psychiatric medication (mood stabilizers alone, atyp-
ical antipsychotics alone, or atypical antipsychotics
plus mood stabilizers) because smoking status [35, 36],
bipolar disorder subtype [37], illness duration [38, 39], and
psychiatric medications [40, 41] potentially influence the
clinical outcomes. In addition, we observed that MetS was
associated with more previous hospitalizations, severer
tardive dyskinesia, poorer insight, poorer global function-
ing, and more impaired cognitive executive function. The
current results supported our hypothesis that patients
with comorbid bipolar disorder and MetS associate with
the severity of neurodegenerative processes and cognitive
impairment than those without [23, 50]. MetS can elicit
inflammatory response (increase in the number of reactive
astrocytes as well as the levels of interleukin-1-beta and
tumor necrosis factor-alpha) and oxidative stress (reactive
oxygen species and lipid peroxidation), causing a reduc-
tion in the number of neurons in the temporal cortex and
hippocampus [23, 51]. Hyperglycemia can directly affect
neuron myelin or axons and the structure and function of
endoneurial microvessels, which can then induce fiber
changes by altering the blood–nerve barrier and inducing
hypoxia or ischemia or through unknown mechanisms
[52]. The positive association between MetS and cognitive
dysfunction was documented with volume losses in the
hippocampus and frontal lobes [53]. Significant correla-
tions between brain microstructural white matter alter-
ations and cognitive impairment have also been noted in
patients with MetS, particularly in the frontal lobe [54].
MetS negatively affects cognitive performance and brain
structure. Potential explanatory models include impaired
vascular reactivity, neuroinflammation, oxidative stress,
and abnormal brain lipid metabolism [53]. Patients with
MetS may also experience a substantial negative economic
and health impact, considerably reducing their quality of
life and social function [11, 12, 55–57].
Notably, in multivariate regression analyses, our
patients with comorbid bipolar disorder and MetS had
severer tardive dyskinesia than did those without. Studies
have suggested that patients with affective disorder treated
with antipsychotics have a greater risk of tardive dyskinesia
[58]. Nevertheless, we adjusted for the pharmacological
treatment duration and psychiatric medication (mood sta-
bilizers alone, atypical antipsychotics alone, or atypical anti-
psychotics plus mood stabilizers) in the multivariate
regression analyses. The association between MetS and
tardive dyskinesia cannot be entirely explained by the
pharmacological treatment. The pathophysiology of tardive
dyskinesia remains to be completely understood. In
addition to the leading hypothesis of dopamine recep-
tor hypersensitivity with antipsychotic treatment, a
crucial pathophysiological theory of tardive dyskinesia
involves neurotoxicity [59]. MetS can elicit inflamma-
tory response and oxidative stress, reducing the num-
ber of neurons [23, 51]; animal studies have shown
that tardive dyskinesia is associated with inflammation
and apoptosis [60, 61]. Furthermore, the potent anti-
oxidants vitamins E and B6 as well as piracetam have
been shown to alleviate the severity of tardive dyskin-
esia in randomized, double-blind, placebo-controlled
studies [62, 63]. In addition, the severity of tardive
dyskinesia is positively associated with that of cogni-
tive dysfunction [64–66], significantly reduced gray
matter, and widespread abnormality of white matter
over corticobasal ganglion circuits, which involves
emotional and behavioral regulation as well as executive
function [67, 68]. Taken together, these studies further
support our results that patients with MetS have severer
tardive dyskinesia and are characterized by severer neuro-
degeneration and poorer clinical outcomes.
Strengths and limitations
Our study investigated the association between MetS
and clinical outcomes in patients with bipolar disorder.
The current results indicate that monitoring MetS is
important for both physical and psychiatric outcomes in
patients with bipolar disorder. Although the exact causes
of MetS in bipolar disorder vary across patients, the
etiological cascade—including biological, psychological,
and sociodemographic variables— ultimately affects the
clinical outcomes of the patients, whether directly or in-
directly. The results also highlight the need for collab-
orative care among psychiatric and general medical
providers to concomitantly address the psychiatric and
other medical needs of patients with bipolar disorder.
However, our study has some limitations, mainly
because of its cross-sectional design. First, whether the
association between MetS and adverse clinical outcomes
of bipolar disorder is causal remains to be determined.
The presence of MetS may lead to more severe neurode-
generation process and cause adverse clinical outcomes;
by contrast, patients with poorer clinical outcomes may
develop MetS because they receive more complex com-
bination therapy. Nevertheless, even more, probable is
the pathophysiology change of MetS and adverse clinical
outcomes occur simultaneously and interact intermingle
with each other. Long-term studies are needed to eluci-
date whether the processes of MetS and clinical out-
comes are distinguishable. Second, even though the
current psychiatric medication groups were controlled
for in the multivariate regression analyses, the impacts
of previous psychiatric medications were difficult to
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investigate. The average treatment duration was 13 years
among our patients, and their previous medications in-
volved varying combinations and treatment durations.
Thus, clarifying the role of a specific medication in the
development of MetS as well as their influence on
clinical outcomes or cognitive function was difficult.
Prospective studies examining patients with the newly
diagnosed bipolar disorder are required. Third, our study
participants were clinically stable outpatients; hence, a
generalization of the results to the entire population of
patients with bipolar disorder may be limited.
Conclusion
The prevalence of MetS in the 143 clinically stable out-
patients with bipolar disorder was 29.4%. The patients
treated with atypical antipsychotics plus mood stabilizers
(36.3%) and atypical antipsychotics alone (36.0%) had a
significantly higher prevalence of MetS than did those
treated with mood stabilizers alone (10.5%). The efficacy
advantages of antipsychotics in bipolar disorder should
be balanced with its greater risk of MetS. The patients
with comorbid bipolar disorder and MetS have adverse
clinical outcomes than those without, with more hospi-
talizations, more tardive dyskinesia, poorer insight,
poorer global function, and more impaired executive
function. The current results supported our hypothesis
that patients with comorbid bipolar disorder and MetS
associated with the severity of neurodegenerative pro-
cesses than those without. Monitoring of metabolic
syndrome is not only important for physical burden, as
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